Recent News

• 09.02.2025 - Replimune Announces Type A Meeting Scheduled with FDA
• 09.02.2025 - Replimune Announces Type A Meeting Scheduled with FDA
• 09.02.2025 - Replimune Announces Type A Meeting Scheduled with FDA
• 08.07.2025 - Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
• 08.07.2025 - Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
• 07.22.2025 - Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
• 07.22.2025 - Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
• 07.22.2025 - Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
• 07.11.2025 - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 07.11.2025 - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 08.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.07.2025 - 8-K Current report
• 08.07.2025 - EX-99.1 EX-99.1
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.31.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.25.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 07.25.2025 - DEF 14A Other definitive proxy statements
• 07.25.2025 - ARS Annual Report to Security Holders
• 07.22.2025 - EX-99.1 EX-99.1
• 07.22.2025 - 8-K Current report